2003 issue 4


Volume 19, issue 4


Pharmacogenomics of lithium in bipolar affective illness

Aleksandra Suwalska1, Janusz Rybakowski1
1. Klinika Psychiatrii Dorosłych Akademii Medycznej w Poznaniu
Farmakoterapia w Psychiatrii i Neurologii, 2003, 4, 85-93
Keywords: bipolar disorder, lithium, pharmacogenomic study


Mechanism of action of lithium – mood-noralizing drug which efficacy in bipolar affective disorder is best established-includes influence on transmembrane ion transport, on neurotransmission, especially serotonergic and dopaminergic, second messenger systems, and neuronal plasticity. In the article, the review of studies on the association between lithium prophylaxis in bipolar affective illness and polymorphism of genes candidates involved in the above processes has been presented.